Choroideremia

CHM SURVEY TRIAL

Dec 01 2020

Choroideremia (CHM) Health Outcomes Sponsor: Biogen MA, Inc.

Sep 30 2020

Natural History of the Progression of Choroideremia Study (NIGHT) Sponsor: NightstaRx Ltd, a Biogen Company CLINICALTRIALS.GOV

Sep 30 2020

A Randomized, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) (STAR) Sponsor: NightstaRx…